The Bob Harrington Show Titelbild

The Bob Harrington Show

The Bob Harrington Show

Von: Medscape
Jetzt kostenlos hören, ohne Abo

Nur 0,99 € pro Monat für die ersten 3 Monate

Danach 9.95 € pro Monat. Bedingungen gelten.

Über diesen Titel

The Bob Harrington Show is a podcast series of thoughtful interviews and discussions on topics at the core of cardiology and the practice of medicine.Copyright 2019, Medscape Hygiene & gesundes Leben Wissenschaft
  • Stroke, Dementia, Voodoo Death: The Heart-Brain Connection
    Jan 26 2026

    Cardiologist Bob Harrington talks to Mitch Elkind, chief science officer for Brain Health and Stroke at the AHA, about the heart-brain connection and why what's good for the brain is good for the heart.

    This podcast is intended for healthcare professionals only.

    To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington

    Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association https://www.ahajournals.org/doi/10.1161/CIR.0000000000001078

    Migraine Headache: An Under-Appreciated Risk Factor for Cardiovascular Disease in Women https://www.ahajournals.org/doi/10.1161/JAHA.119.014546

    Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands

    https://doi.org/10.1080/13814788.2017.1398318

    Characteristics and treatment of midlife-onset epilepsy: A 24-year single-center, retrospective study

    https://doi.org/10.1002/epd2.20253

    Traumatic Brain Injury and Risk of Neurodegenerative Disorder

    https://doi.org/10.1016/j.biopsych.2021.05.025

    Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence

    https://doi.org/10.3390/ijms222413488

    The neuropathological diagnosis of Alzheimer's disease

    https://doi.org/10.1186/s13024-019-0333-5

    Failed Semaglutide for Early Alzheimer's Not the End of the Road?

    https://www.medscape.com/viewarticle/failed-semaglutide-early-alzheimers-not-end-road-2025a1000y4l

    Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration

    https://doi.org/10.1161/circulationaha.121.055018

    Reduced regional cerebral blood flow in patients with heart failure

    https://doi.org/10.1002/ejhf.874

    Heart-brain Interactions in Heart Failure

    https://doi.org/10.15420/cfr.2018.14.2

    While You Were Sleeping, the Brain's 'Waste Disposal System' Was at Work

    https://www.medscape.com/viewarticle/while-you-were-sleeping-brains-waste-disposal-system-was-2025a1000mbb

    Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder

    https://doi.org/10.1001/jamapsychiatry.2024.3599

    2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356

    "VOODOO" Death https://ajph.aphapublications.org/doi/full/10.2105/AJPH.92.10.1593

    Longitudinal brain ageing after stroke: a marker for neurodegeneration and its relevance for upper limb motor outcome https://doi.org/10.1093/braincomms/fcaf299

    Unlocking Longevity: Aging Reimagined https://www.medscape.com/viewarticle/1002241

    You may also like:

    Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

    https://www.medscape.com/twic

    Questions or feedback, please contact news@medscape.net

    Mehr anzeigen Weniger anzeigen
    24 Min.
  • Cardiovascular Medicine 2025 Wrapped: The Big Picture
    Dec 30 2025

    Drs Harrington and Gibson's annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights.

    This podcast is intended for healthcare professionals only.

    To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington

    New ACS Guidelines

    2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes

    https://doi.org/10.1161/CIR.0000000000001309

    ACS Guideline Chair and Vice-Chair Discussion

    https://www.medscape.com/viewarticle/acs-guidelines-2025-key-points-chair-and-vice-chair-2025a100093l

    Antiplatelet/Antithrombotic Strategies

    Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI

    https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt

    Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET)

    https://www.nejm.org/doi/full/10.1056/NEJMoa2507980

    Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC)

    https://www.nejm.org/doi/full/10.1056/NEJMoa2507532

    Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making : ENGAGE AF-TIMI 48 Trial Analysis

    https://doi.org/10.1016/j.jacadv.2025.102504

    Factor XI Inhibitors

    Bristol Myers, J&J Stop Blood Clotting Drug Trial After Interim Review

    https://www.medscape.com/s/viewarticle/bristol-myers-j-j-stop-blood-clotting-drug-trial-after-2025a1000vqu

    Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention https://www.bayer.com/en/us/news-stories/oceanic-stroke

    OAC-Naive Subgroup From OCEANIC-AF Published

    https://www.medscape.com/viewarticle/novel-blood-thinner-shows-promise-atrial-fibrillation-2025a10008lz

    GLP-1 and Myotrophic Drugs

    Lilly's Next-gen Drug Shows Greater Weight Loss Than Zepbound in Late-stage Trial (TRIUMPH-4)

    https://www.medscape.com/s/viewarticle/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-2025a1000ys1

    Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial

    https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf

    CRISPR and Lipid Lowering

    Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease

    https://www.nejm.org/doi/full/10.1056/NEJMoa2504747

    Gene Therapy Shows Lipid Improvement but Raises Flags

    https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw

    Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3

    https://www.nejm.org/doi/full/10.1056/NEJMoa2511778

    Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (VESALIUS-CV)

    https://www.nejm.org/doi/pdf/10.1056/NEJMoa2514428

    Prehospital GLP IIb/IIIa

    Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268

    You may also like:

    Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

    https://www.medscape.com/twic

    Questions or feedback, please contact news@medscape.net

    Mehr anzeigen Weniger anzeigen
    32 Min.
  • SMuRF-less: CV Prevention Beyond Traditional Risk Factors
    Oct 29 2025

    Drs Harrington, Rodriguez, and Ridker discuss the changing field of cardiac prevention, where imaging fits in, and the new concept of standard modifiable risk factor-less patients.

    This podcast is intended for healthcare professionals only.

    To read a transcript or to comment, visit

    https://www.medscape.com/author/bob-harrington

    Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association

    https://doi.org/10.1161/CIR.0000000000001078

    Development and Validation of the American Heart Association's PREVENT Equations

    https://doi.org/10.1161/CIRCULATIONAHA.123.067626

    C-Reactive Protein and Cardiovascular Risk Among Women With No Standard Modifiable Risk Factors: Evaluating the 'Smurf-Less but Inflamed'

    https://doi.org/10.1093/eurheartj/ehaf658

    Mortality in STEMI Patients Without Standard Modifiable Risk Factors: A Sex-Disaggregated Analysis of SWEDEHEART Registry Data

    https://doi.org/10.1016/S0140-6736(21)00272-5

    Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women

    https://www.nejm.org/doi/10.1056/NEJMoa2405182

    Statins for the 'SMuRFLess But Inflamed': Silent Vascular Inflammation and the Challenge of Translational Science

    https://doi.org/10.1016/j.jacbts.2025.101318

    VERVE-101: A Promising CRISPR-Based Gene Editing Therapy That Reduces LDL-C and PCSK9 Levels in HeFH Patients

    https://academic.oup.com/ehjcvp/article/10/2/89/7492807

    You may also like:

    Hear John Mandrola, MD, give a summary and his perspective on the top cardiology news each week, on This Week in Cardiology

    https://www.medscape.com/twic

    Questions or feedback, please contact news@medscape.net

    Mehr anzeigen Weniger anzeigen
    24 Min.
Noch keine Rezensionen vorhanden